RBC Capital analyst Randall Stanicky maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Tuesday, setting a price target of $180, which is approximately 18.80% above the present share price of $151.51.
Stanicky expects Jazz Pharmaceuticals to post earnings per share (EPS) of $2.67 for the fourth quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $184.42.
The analysts price targets range from a high of $233 to a low of $145.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $600.89 million and a net profit of $206.21 million. The company's market cap is $8.39 billion.
According to TipRanks.com, RBC Capital analyst Randall Stanicky is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.8% and a 39.02% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.